The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost-effectiveness threshold

It has been suggested that scepticism among decision-makers about using cost-effectiveness analysis (CEA) is caused in part by the low level of the cost-effectiveness 'thresholds' in the economic evaluation literature. This has led Ubel and colleagues to call for higher threshold values of US$200,000 or more per quality-adjusted life-year. We show that these arguments fail to identify the objective of CEA and hence do not consider whether or how the threshold relates to this objective. We show that incremental cost-effectiveness ratios (ICERs) cannot be used to identify an efficient use of resources – the 'biggest bang for the bucks' – allocated to health care. On the contrary, the practical consequence of using the ICER approach is shown to be an increase in health care expenditures, or 'bigger bucks for making a bang', without any evidence of the bang being bigger (i.e. that this leads to an increase in benefits to the population). We present an alternative approach that provides an unambiguous method of determining whether a new intervention leads to an increase in health gains from whatever resources are to be made available to health care decision-makers.

[1]  Richard J. Zeckhauser,et al.  Critical ratios and efficient allocation , 1973 .

[2]  M. Weinstein,et al.  Foundations of cost-effectiveness analysis for health and medical practices. , 1977, The New England journal of medicine.

[3]  Michael Drummond,et al.  Principles of economic appraisal in health care , 1980 .

[4]  M C Weinstein,et al.  Use and misuse of the term "cost effective" in medicine. , 1986, The New England journal of medicine.

[5]  A Gafni,et al.  Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be? , 1992, Journal of health economics.

[6]  A S Detsky,et al.  How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[7]  A. Gafni,et al.  Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems. , 1993, Journal of health economics.

[8]  A Gafni,et al.  Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. , 1993, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[9]  M. Johannesson The relationship between cost-effectiveness analysis and cost-benefit analysis. , 1995, Social science & medicine.

[10]  M. Mcgrath Cost Effectiveness in Health and Medicine. , 1998 .

[11]  A H Briggs,et al.  Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane. , 2001, Health economics.

[12]  A Gafni,et al.  Opportunity costs and uncertainty in the economic evaluation of health care interventions. , 2002, Health economics.

[13]  C. Zinn Australia's plan to reduce drug spending attacked by doctors , 2002, BMJ : British Medical Journal.

[14]  Andreas Laupacis,et al.  Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones? , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[15]  Richard Edlin,et al.  Is it really possible to build a bridge between cost-benefit analysis and cost-effectiveness analysis? , 2002, Journal of health economics.

[16]  K. Levit,et al.  Trends in U.S. health care spending, 2001. , 2003, Health affairs.

[17]  Peter A Ubel,et al.  What is the price of life and why doesn't it increase at the rate of inflation? , 2003, Archives of internal medicine.

[18]  S. Morgan,et al.  Whither seniors' pharmacare: lessons from (and for) Canada. , 2003, Health affairs.

[19]  Alan Williams,et al.  What Could be Nicer than NICE , 2004 .